JP2012528190A5 - - Google Patents

Download PDF

Info

Publication number
JP2012528190A5
JP2012528190A5 JP2012513260A JP2012513260A JP2012528190A5 JP 2012528190 A5 JP2012528190 A5 JP 2012528190A5 JP 2012513260 A JP2012513260 A JP 2012513260A JP 2012513260 A JP2012513260 A JP 2012513260A JP 2012528190 A5 JP2012528190 A5 JP 2012528190A5
Authority
JP
Japan
Prior art keywords
igg
ultrafiltration
ultrafiltration membrane
diafiltration
ultra
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012513260A
Other languages
English (en)
Japanese (ja)
Other versions
JP5341252B2 (ja
JP2012528190A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/036430 external-priority patent/WO2010138736A2/en
Publication of JP2012528190A publication Critical patent/JP2012528190A/ja
Publication of JP2012528190A5 publication Critical patent/JP2012528190A5/ja
Application granted granted Critical
Publication of JP5341252B2 publication Critical patent/JP5341252B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012513260A 2009-05-27 2010-05-27 皮下使用の高濃度免疫グロブリン製剤を生成する方法 Active JP5341252B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18160609P 2009-05-27 2009-05-27
US61/181,606 2009-05-27
PCT/US2010/036430 WO2010138736A2 (en) 2009-05-27 2010-05-27 A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use

Publications (3)

Publication Number Publication Date
JP2012528190A JP2012528190A (ja) 2012-11-12
JP2012528190A5 true JP2012528190A5 (enExample) 2013-07-11
JP5341252B2 JP5341252B2 (ja) 2013-11-13

Family

ID=42335649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513260A Active JP5341252B2 (ja) 2009-05-27 2010-05-27 皮下使用の高濃度免疫グロブリン製剤を生成する方法

Country Status (18)

Country Link
US (5) US8546548B2 (enExample)
EP (3) EP2762492A3 (enExample)
JP (1) JP5341252B2 (enExample)
KR (1) KR101464032B1 (enExample)
CN (1) CN102459331B (enExample)
AR (1) AR076607A1 (enExample)
AU (6) AU2010253830B2 (enExample)
BR (1) BRPI1012082B1 (enExample)
CA (1) CA2763138A1 (enExample)
CL (2) CL2011002996A1 (enExample)
CO (1) CO6480954A2 (enExample)
EA (1) EA023382B1 (enExample)
HK (1) HK1200843A1 (enExample)
MX (1) MX2011012576A (enExample)
MY (1) MY157239A (enExample)
SG (1) SG176256A1 (enExample)
TW (1) TWI445714B (enExample)
WO (1) WO2010138736A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
EP4786482A2 (en) 2009-08-06 2026-08-05 F. Hoffmann-La Roche AG Virus filtration methods
PT2477603E (pt) * 2009-09-17 2016-06-16 Baxalta Inc Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
FR2962650B1 (fr) * 2010-07-19 2013-04-05 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
PL2616090T3 (pl) 2010-09-17 2023-12-18 Takeda Pharmaceutical Company Limited Stabilizowanie immunoglobulin poprzez wodną formulację z histydyną o ph od słabo kwaśnego do obojętnego
FR2974301B1 (fr) 2011-04-20 2013-08-23 Lab Francais Du Fractionnement Procede de preparation d'un produit plasmatique deplete en un ou plusieurs facteurs thrombogenes
FR2977893B1 (fr) * 2011-07-11 2015-02-20 Lab Francais Du Fractionnement Procede de preparation d'un concentre d'immunoglobulines polyvalentes
CA2846599A1 (en) 2011-08-26 2013-03-07 Baxter International Inc. Method for reducing the thromboembolic potential of a plasma-derived immunoglobulin composition
DK2758076T3 (en) 2011-09-24 2019-04-01 Csl Behring Gmbh COMBINATION THERAPY USING IMMUNOGLOBULIN AND C1 INHIBITOR
WO2013090636A1 (en) 2011-12-13 2013-06-20 Baxter International Inc. Measurement of autoantibodies at low conductivity conditions with increased sensitivity
CN102532307B (zh) * 2012-02-22 2013-06-12 成都蓉生药业有限责任公司 一种制备人免疫球蛋白的方法
TWI629283B (zh) * 2012-02-23 2018-07-11 巴克斯歐塔公司 來自血漿中的免疫球蛋白之ｉ-ｉｖ-１部分沉澱
US20150157619A1 (en) * 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
WO2014018747A2 (en) 2012-07-26 2014-01-30 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
WO2014135694A1 (en) 2013-03-08 2014-09-12 Csl Behring Ag Treatment and prevention of remote ischemia-reperfusion injury
AU2013203043B2 (en) * 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
ES2708759T3 (es) 2013-05-13 2019-04-11 Momenta Pharmaceuticals Inc Procedimientos para el tratamiento de la neurodegeneración
EP3058084A4 (en) 2013-10-16 2017-07-05 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
CN115177759B (zh) * 2013-11-15 2024-07-23 豪夫迈·罗氏有限公司 使用环保洗涤剂的病毒灭活方法
WO2016161418A1 (en) * 2015-04-02 2016-10-06 Kieu Hoang A method of manufacturing an afod intra venous injection from fraction iv
CA2986957A1 (en) 2015-06-03 2016-12-08 Children's Hospital Medical Center Compositions and methods for treating neonatal biliary atresia
US11186858B1 (en) 2016-03-15 2021-11-30 Fresenius Kabi Deutschland Gmbh Methods for increasing biosimilarity
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses
FR3081328B1 (fr) * 2018-05-24 2021-01-01 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines concentrees
KR102337683B1 (ko) * 2018-09-21 2021-12-13 주식회사 녹십자 고효율 항-tfpi 항체 조성물
KR20220002963A (ko) * 2019-04-18 2022-01-07 얀센 바이오테크 인코포레이티드 시알릴화된 당단백질
US20250188120A1 (en) 2022-03-07 2025-06-12 Takeda Pharmaceutical Company Limited Affinity chromatographic production of clinical human igg products
CN117069836B (zh) * 2023-09-22 2024-08-27 武汉中生毓晋生物医药有限责任公司 一种抗人t细胞兔免疫球蛋白的制备方法
AU2024351533A1 (en) * 2023-09-26 2026-03-19 Takeda Pharmaceutical Company Limited IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US4056614A (en) 1972-09-22 1977-11-01 Marc Bonneau Immunity depressant medicine
US3998946A (en) 1975-04-23 1976-12-21 The Regents Of The University Of Minnesota Fibrinogen-free plasminogen-plasmin-free plasma and method of preparing and using same
DE2801123C2 (de) 1977-01-26 1986-01-02 Armour Pharma GmbH & Co KG, 3440 Eschwege Verfahren zur Herstellung eines intravenös applizierbaren Serumeiweiß-Präparates
US4296027A (en) 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
US4136094A (en) * 1977-08-31 1979-01-23 The Regents Of The University Of Minnesota Preparation of intravenous human and animal gamma globulins and isolation of albumin
US4550019A (en) 1978-03-22 1985-10-29 South Africa Inventions Development Corporation Manufacture and use of fowl egg antibodies
DE2901822A1 (de) 1979-01-18 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung einer fuer die intravenoese applikation geeigneten immunglobulinloesung, die igm in ankonzentrierter form enthaelt
DE2902158A1 (de) 1979-01-20 1980-07-31 Biotest Serum Institut Gmbh Verfahren zur herstellung von fibrinogen, einem die gerinnungsfaktoren ii, vii, ix und x enthaltenden prothrombinkomplex, antithrombin iii und einer loesung von lagerstabilen serumproteinen
US4228154A (en) 1979-02-26 1980-10-14 Armour Pharmaceutical Company Purification of plasma albumin by ion exchange chromatography
US4378346A (en) 1979-08-15 1983-03-29 Tankersley Donald L Intravenously injectable solution of plasma protein fraction free from bradykinin, kininogen and prekallikrein activators and processes for its production
US4499073A (en) 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
JPS5855432A (ja) 1981-09-29 1983-04-01 Fujirebio Inc 静脈注射用免疫グロブリンの製法
US4439358A (en) 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4624780A (en) 1982-06-28 1986-11-25 Alpha Therapeutic Corporation Fractionation of blood plasma
DE3247150A1 (de) 1982-12-21 1984-06-28 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Gerinnungsaktive plasmaproteinloesung, verfahren zu ihrer herstellung und ihre verwendung zur behandlung von stoerungen des haemostasesystems
DK166763B1 (da) 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
US5061237A (en) 1985-07-02 1991-10-29 Cytomed Medizintechnik Gmbh Method of purifying whole blood
DE3523615A1 (de) 1985-07-02 1987-01-15 Cytomed Medizintechnik Medizinisches geraet, insbesondere kanuele, katheter oder implantat
JPH0742235B2 (ja) 1985-11-08 1995-05-10 三共株式会社 自己免疫性疾病の予防・治療剤
US5136094A (en) 1988-03-10 1992-08-04 Air Products And Chemicals, Inc. Process for the synthesis of secondary formamides
US5055447A (en) 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
DE3929411A1 (de) 1988-09-22 1990-03-29 Siegfried Natterer Pharmazeutische zubereitung sowie verfahren zu ihrer herstellung
US4892826A (en) 1988-10-11 1990-01-09 Abbott Laboratories Process for the preparation of urokinase derivatives
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
JP2871709B2 (ja) 1988-11-21 1999-03-17 住友製薬株式会社 免疫グロブリンｇ結合活性を有する新規な蛋白質プロテインｈ、該蛋白質をコードする遺伝子及び該蛋白質の製造法
US5177194A (en) 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
EP0440509A3 (en) 1990-02-02 1991-12-18 Common Services Agency Novel cell growth medium components and process for producing same
EP0447585B2 (de) 1990-03-22 2003-05-07 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verträglichen Immunglobulin-G-Präparates
AT402261B (de) 1991-01-25 1997-03-25 Immuno Ag Komplex enthaltend den gerinnungsfaktor ix
US5130451A (en) 1991-03-28 1992-07-14 Amoco Corporation Process for preparing carboxyaryl phosphates
US5324425A (en) 1992-08-26 1994-06-28 Ellison Billy L Method and apparatus for removing solids from aqueous wash solutions
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
FR2711371B1 (fr) 1993-10-18 1995-12-29 Aetsrn Procédé de préparation d'un concentré d'inter-alpha-trypsine inhibiteur à usage thérapeutique et concentré obtenu.
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
DE4435485C1 (de) 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AUPN858596A0 (en) 1996-03-08 1996-04-04 Csl Limited Filtration of plasma precipitates using cellulose filter aid
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2232420A1 (en) 1997-03-19 1998-09-19 The Green Cross Corporation Immunoglobulin preparation and preparation process thereof
GB9705810D0 (en) 1997-03-20 1997-05-07 Common Services Agency Intravenous immune globulin
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
AT405739B (de) 1997-09-19 1999-11-25 Immuno Ag Verfahren zur reinigung von antithrombin iii
CA2251342A1 (en) 1997-10-23 1999-04-23 Yutaka Hirao Room temperature storable immunoglobulin preparation for intravenous injection
US20020114802A1 (en) 1998-02-10 2002-08-22 Tjellstrom Bo Arthur Einar Oral immunoglobulin treatment for inflammatory bowel disease
AT406873B (de) 1998-02-25 2000-10-25 Immuno Ag Verfahren zur abreicherung von pathogenen aus proteinhaltigen lösungen
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
ID27417A (id) * 1998-06-09 2001-04-05 Statens Seruminstitut Proses untuk memproduksi immunoglobulin untuk pemberian melalui intravena dan produk-produk immunoglobulin lainnya
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
DE19932782A1 (de) 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
DE10008619A1 (de) 2000-02-24 2001-09-06 Immuno Vet As Lynge Mikroorganismenfreies IgG-Präparat, Verfahren zu seiner Herstellung und seine Verwendung in der Tieraufzucht und in der Tiermast
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US6962700B1 (en) 2000-09-13 2005-11-08 Atopix Pharmaceuticals Corporation Method of manufacturing immune globulin
US20020098182A1 (en) 2000-09-28 2002-07-25 Richard Weisbart Treatment of immune-mediated diseases by oral administration of plasma fractions enriched in immunoglobulin G
AU2002216968A1 (en) 2000-10-13 2002-04-22 Octapharma Ag Plasma fraction containing bikunin, method for the production thereof and use of the same
FR2824568B1 (fr) 2001-05-11 2004-04-09 Lab Francais Du Fractionnement Procede de preparation de concentres d'immunoglobulines humaines a usage therapeutique
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US6893639B2 (en) 2001-10-19 2005-05-17 Hemacare Corporation Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
WO2005012354A1 (en) 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1664119A1 (en) 2003-09-08 2006-06-07 Medical Research Council Method for the treatment or prophylaxis of tuberculosis
US20050054003A1 (en) 2003-09-10 2005-03-10 Stenland Christopher J. Prion clearance using particulate metal oxides
US7932365B2 (en) 2003-11-08 2011-04-26 Pro Thera Biologics, Llc Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US7745389B2 (en) 2005-02-14 2010-06-29 University Of Iowa Research Foundation Methods for treatment of age-related macular degeneration
US8715649B2 (en) 2005-06-07 2014-05-06 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods of use for alpha-1 antitrypsin having no significant serine protease inhibitor activity
WO2009005877A2 (en) 2007-04-20 2009-01-08 Regents Of The University Of Colorado Alpha-i antitrypsin having no significant serine protease inhibitor activity
JP2009508822A (ja) 2005-09-19 2009-03-05 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 慢性腎症の処置のためのｈ因子およびその製造
FR2894145B1 (fr) 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
EP1987054A1 (en) 2006-01-25 2008-11-05 Octapharma AG Purification and use of a factor for supporting wound healing
US8476234B2 (en) 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
ES2595059T3 (es) 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
PL2167117T3 (pl) 2007-06-13 2013-01-31 Csl Behring Gmbh Zastosowanie stabilizowanego VWP preparatu FVIII do podawania pozanaczyniowego w terapii i profilaktyce zaburzeń krzepliwości krwi
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
JP5400050B2 (ja) 2007-10-02 2014-01-29 シーエスエル、リミテッド 治療用抗体の精製法および使用法
CN101279246B (zh) * 2007-12-28 2011-07-27 华侨大学 一种嗜硫性磁性复合微球的制备方法和用此复合微球分离免疫球蛋白g的方法
EP2244814B1 (en) 2007-12-28 2021-06-02 Takeda Pharmaceutical Company Limited Recombinant vwf formulations
CN101249265B (zh) 2008-04-11 2010-10-27 三九集团湛江开发区双林药业有限公司 静脉注射用人乙肝免疫球蛋白及其制备方法
PT2271382E (pt) * 2008-04-15 2013-05-07 Grifols Therapeutics Inc Ultrafiltração em dois andares/diafiltração
JP5793076B2 (ja) 2008-05-28 2015-10-14 プロセラ バイオロジクス， インコーポレイテッド 血液由来インター−アルファ−阻害タンパク質の調製及び組成物。
EP2865760B1 (en) 2008-06-24 2017-10-11 CSL Behring GmbH Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
CN201169579Y (zh) 2008-06-30 2008-12-24 山东泰邦生物制品有限公司 一种人血白蛋白分离用乙醇雾化扩散装置
EP2349314B1 (en) 2008-10-21 2013-02-27 Baxter International Inc. Lyophilized recombinant vwf formulations
WO2010056909A1 (en) 2008-11-12 2010-05-20 Baxter International Inc. Purification of butyrylcholinesterase using membrane adsorption
US8546548B2 (en) * 2009-05-27 2013-10-01 Baxter International Inc. Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
WO2011011753A1 (en) 2009-07-23 2011-01-27 Baxter International Inc. Manufacture of factor h (fh) and fh-derivatives from plasma
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
EA202090067A3 (ru) 2010-07-08 2020-07-31 Баксалта Инкорпорейтид Способ получения рекомбинантного adamts13 в культуре клеток
EP2596014B1 (en) 2010-07-23 2018-11-28 Baxalta GmbH Manufacture of inter-alpha-inhibitor proteins (iaip) from plasma

Similar Documents

Publication Publication Date Title
CA2941232C (en) Method for purifying immunoglobulin
RU2603347C2 (ru) Очистка белка с использованием бис-трис буфера
ES2536093T3 (es) Procedimiento para preparar una composición de IgG enriquecida a partir de plasma
RU2337109C2 (ru) ПРЕПАРАТ ИММУНОГЛОБУЛИНА IgG И СПОСОБ ЕГО ПОЛУЧЕНИЯ
CA2941230C (en) Method for purifying immunoglobulin
JP2013527201A5 (enExample)
JP2013530950A5 (enExample)
CA2796409A1 (en) Process for preparing an immunoglobulin composition
CN104245730A (zh) 源自血浆的免疫球蛋白的级分i-iv-1沉淀
CA3080108A1 (en) Improved method for purification of immunoglobulin
ITFI20090273A1 (it) Nuovo processo di purificazione su scala industriale di gammaglobuline da plasma umano per uso industriale.
JP2023532473A (ja) ヒト血漿由来免疫グロブリンｍを含む組成物を得るための方法
CN102532307A (zh) 一种制备人免疫球蛋白的方法
TW201307384A (zh) 多價免疫球蛋白之濃縮物之製造方法
EP3305800B1 (en) Preparation method of plasma-derived hepatitis b human immunoglobulin agent
CN111944043B (zh) 一种从血浆废弃物中提取IgM的方法
JP2025512143A (ja) 酸化ケイ素吸着を使用する血漿からのｆｖｉｉｉの精製
AR129192A1 (es) Fraccionamiento de plasma mediante un agrupamiento de cohn concentrado como materia prima
JP2025514479A5 (enExample)
TW388763B (en) Method of producing a hyper immunoglobulin preparation from fractions produced druing fractionation of human blood plasma
KR20230148961A (ko) 면역글로불린 정제방법
WO2025085544A1 (en) Integrated process for isolation of plasma proteins
KR102372105B1 (ko) 면역글로블린의 제조방법
CN121985959A (zh) 耗减IgA的免疫球蛋白制剂
HK1057375A (en) A method of producing igg